Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Choroidal Neovascularization, Age-Related Maculopathy

In brief

The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Key facts

Study ID

NCT00511706

Run by

Allergan

People needed

243

Starts

2007-11-01

Expected to finish

2009-03-01

Last updated by the study team

2019-04-25

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 50 years of age or older with subfoveal choroidal neovascularization (CNV) (classic and/or occult) secondary to AMD
• Visual Acuity between 20/40 and 20/400 in the study eye

You may not qualify if…

• Any intraocular surgery within 3 months
• Glaucoma
• Cataract
• High eye pressure
• Uncontrolled systemic disease

Where it is running

• Study site — Boynton Beach, Florida, United States
• Study site — Parramatta, New South Wales, Australia
• Study site — Paris, France
• Study site — Tel Aviv, Israel
• Study site — Milan, Italy
• Study site — Auckland, New Zealand
• Study site — Coimbra, Portugal
• Study site — Seoul, South Korea
• Study site — Southampton, Hampshire, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.